Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
A group of mice were administered with a mixture of cyclophosphamide and normal saline using intraperitoneal injection while the test group was injected with cyclophosphamide and extract of H
ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update Cash position of 9.7 million as of June 30, 2026 Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027 BioChaperone feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies Regulatory News: Adocia (Euronext Paris: FR0011184241 ADOC, the Company), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update
The pathway genes with strong constitutive GAP promoters were introduced into the genome of W303-1b via homologous integration at -sites
January 2022
Symptom logs and advanced markers like MMA can guide this switch more effectively than B12 blood levels alone
Enhanced oxidative capacity may involve increased mitochondrial fatty acid uptake via carnitine palmitoyltransferase-1 (CPT-1), enhanced beta-oxidation enzyme expression, and modulation of uncoupling protein expression
US$ 27.48
US$ 23.56
US$ 20.85
US$ 26.85
US$ 27.35
US$ 26.98